Biomedical Research

Research Article - Biomedical Research (2017) Volume 28, Issue 15

Interleukin-6 rs1800795 polymorphism is not a risk factor of hypertension

Sheng Yue1,2, Jian Jia3, Ning Zhang1, Yi-Yang Zhan1* and Hai-Xia Ding4

1Department of Geratic Cardiology, the First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, PR China

2Department of Emergency, Luo Yang Central Hospital affiliated to Zhengzhou University, Luoyang, Henan, PR China

3Department of General Medicine, the First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, PR China

4Department of Geratic Neurology, the First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, PR China

*Corresponding Author:
Yi-Yang Zhan
Department of Geratic Cardiology
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, PR China

Accepted date: July 12, 2017

Visit for more related articles at Biomedical Research

Abstract

The role of IL-6 rs1800795 polymorphism in the development of hypertension has been inclusive. Therefore, the purpose of our study was to determine whether there is an association between IL-6 rs1800795 polymorphism and hypertension risk. PubMed, Embase and China National Knowledge Infrastructure (CNKI) were searched till Jun 2017. A total of 7 case-control studies with 1231 cases and 1122 controls were included. We did not found a significant association between IL-6 rs1800795 polymorphism and the susceptibility to hypertension (OR=0.94; 95% CI, 0.71-1.24; P=0.67). In the subgroup analysis of race, both Asian (OR=1.52; 95% CI, 0.15-15.48; P=0.73) and Caucasian (OR=1.01; 95% CI, 0.84-1.21; P=0.92) with IL-6 rs1800795 polymorphism did not show significant associations. In conclusion, this meta-analysis suggested that IL-6 rs1800795 polymorphism was not associated with the risk of hypertension.

Keywords

IL-6, Hypertension, Genetic, Association

Introduction

Hypertension is a leading risk factor for many disorders including coronary heart disease and stroke, and contributes to approximately 12.8% of annual deaths worldwide [1]. In China, about 153 million (18%) Chinese adults were hypertensive in 2002 [2]. It is estimated that 29.2% (range, 28.8%-29.7%) of the world population will have hypertension by 2025, increasing by about 60% [3]. The causes of hypertension are complex and are correlated with numerous environmental and genetic factors.

Many pro-inflammatory cytokines are known to be involved in the risk of hypertension. Interleukin-6 (IL-6) is mainly originated from mononuclear phagocytes and partly from fibroblasts, T and B lymphocytes, and vascular endothelial cells [4]. IL-6 gene is located at 7p21 and encodes a cytokine that plays a role in inflammation and B cell maturation. In recent years, the role of IL-6 rs1800795 polymorphism in the development of hypertension has been kept exploring [5-11]. However, in most of those studies the sample size was small. Therefore, the purpose of our study was to determine whether there is an association between IL-6 rs1800795 polymorphism and hypertension risk.

Methods

Search strategy

PubMed, Embase and China National Knowledge Infrastructure (CNKI) were searched till to Jun 2017. The search terms were “Interleukin-6”, “IL-6”, “polymorphism” and “hypertension”. In addition, the citations in the retrieved articles were reviewed to search for relevant studies. We also searched previous reviews and meta-analysis.

Criteria for article screening

The studies included must meet the following criteria: (1) The study assessed the association between IL-6 rs1800795 polymorphism and hypertension risk; (2) The study should be case-control or cohort study; (3) Odds Ratio (OR) with the 95% Confidence Interval (CI) was reported.

Data extraction

The following information was extracted from all obtained publications: first author’s name, publication year, ethnicity, age, sample size and Hardy-Weinberg Equilibrium (HWE).

Statistical analysis

The intensity of the relationship between IL-6 rs1800795 polymorphism and the susceptibility to hypertension was calculated with the OR and respective 95% CI. Heterogeneity between selected studies was inspected using chi-square-based Q test, with P value more or less than 0.05, representing the absence or presence of significant heterogeneity. The random-effects model was chosen to calculate the pooled OR. The subgroup analysis was carried out by race. In the sensitivity analysis, we excluded the study without HWE. The presence of publication bias was assessed by a visual inspection of a funnel plot. All statistical tests were used by the Reviewer Manager software.

Results

Characteristics of the studies

Characteristics of the included studies were shown in Figure 1. A total of 7 case-control studies with 1231 cases and 1122 controls were included. Two studies were conducted in Asians and five studies were performed in Caucasians. One study was not in HWE.

biomedres-risk-hypertension

Figure 1: Effect of IL-6 rs1800795 polymorphism on the risk of hypertension.

Meta-analysis

As shown in Figure 1, we did not found a significant association between IL-6 rs1800795 polymorphism and the susceptibility to hypertension (OR=0.94; 95% CI, 0.71-1.24; P=0.67). In the subgroup analysis of race, both Asian (OR=1.52; 95% CI, 0.15-15.48; P=0.73) and Caucasian (OR=1.01; 95% CI, 0.84-1.21; P=0.92) with IL-6 rs1800795 polymorphism did not show significant associations. In the sensitivity analysis, the results were not altered when the study without HWE was excluded. Publication bias was not found in Figure 2.

biomedres-risk-Funnel-plot

Figure 2: Funnel plot of IL-6 rs1800795 polymorphism and the risk of hypertension.

Discussion

In this study, a total of 7 case-control studies with 1231 cases and 1122 controls were included. We did not found a significant association between IL-6 rs1800795 polymorphism and the susceptibility to hypertension. In the subgroup analysis of race, both Asian and Caucasian with IL-6 rs1800795 polymorphism did not show significant associations. In the sensitivity analysis, the results were not altered.

Kim et al. suggested that rs1800795 SNP of IL-6 gene was not related to arterial thromboembolic events [12]. Lorente et al. suggested that IL-6 promoter polymorphism (-174 G/C) might be a favourable genotype in septic patients showing lower serum IL-6 levels and lower risk of death within 30 d [13]. Ruiz-Padilla et al. found that IL-6 -174G/G genotype confers higher risk of failure in therapeutic response to LEF in Mexicans and if confirmed in other populations this can be used as promissory genetic marker to differentiate risk of therapeutic failure to LEF [14]. Kumar et al. suggests that IL-6 gene polymorphisms are not associated with the risk of intracerebral haemorrhage [15]. Hongmei et al. suggested that IL-6 -592G>C polymorphism was correlated with the risk of coronary artery disease [16].

Some limitations were existed in this meta-analysis. First, many of the original studies did not adjust for potentially important confounders. Second, the inconsistency of the base line characteristics between the studies, such as age and gender, might increase the selection bias. Third, due to the lack of original information of the entire data, we did not evaluate interactions of gene and environmental factors in all pooled studies.

In conclusion, this meta-analysis suggested that IL-6 rs1800795 polymorphism was not associated with the risk of hypertension.

References